As a "Patients Helping Patients" organization, MSWorld is supporting the ALS Icebucket Challenge. All donations received by MSWorld from this challenge will go directly to support ALSA.org.
Cognition & Multiple Sclerosis
Want to see the Conference Coverage Information about Cognition and Multiple Sclerosis? You can now view all MSWorld Conference Coverage in regards to this topic by clicking here, or on the search button!
Researchers from Australia and the United Kingdom report that the risk of developing MS was significantly reduced in a population of more than 20,000 people with HIV (human immunodeficiency virus, which causes the acquired immunodeficiency syndrome, or AIDS) infection identified through an English data set. It is not clear whether this association is related to the biological impact of HIV infection or its treatment with anti-viral therapies. Further study is necessary to understand the significance of these results. Julian Gold, MD (Prince of Wales Hospital, Sydney) and colleagues report their findings in the Journal of Neurology Neurosurgery and Psychiatry (published online August 4).
Statistical analyses were done in order to examine how factors such as gender and age at disease onset influenced the amount of time it would take for an individual’s disability to worsen, and to determine if there are phases of early and late disability accumulation in people with primary progressive MS. To measure changes in disability, the researchers looked specifically at the Expanded Disability Status Scale (EDSS) scores for each person. The research team also analyzed whether or not there are different risk factors for rapid versus slow accumulation of disability.
To read this full article, click here. MS Society Canada August 18, 2014
The U.S. Food and Drug Administration has approved Plegridyâ„¢ (peginterferon beta-1a, Biogen Idec) as a new disease-modifying therapy for people with relapsing forms of MS. Peginterferon beta-1a, injected under the skin every two weeks, is a new therapy that belongs to the same interferon class as several medications that have been approved to treat MS. This new version is designed to maintain the effects of interferon in the body for a longer period of time. Plegridy is expected to be available by prescription in mid-September.
To read this full article, click here. National MS Society - August 15, 2014
SPECIAL NOTE: If you have a pop-up blocker you may not be able to view links listed in this newsletter. You can set your blocker to temporarily allow pop-ups.
Information shared on all aspects of MSWorld.org is not intended to be used towards the diagnosis or treatment of any medical condition. For specific information and advice, consult your personal physician. - MSWorld Management
MSWorld provides the message board and chat services for the National MS Society. We are proud to have been a collaborative partner with the NMSS since 2001.
